Journal of the American Academy of Child & Adolescent Psychiatry
ARTICLESComparison of Increasingly Detailed Elicitation Methods for the Assessment of Adverse Events in Pediatric Psychopharmacology
Section snippets
Subjects
Children of either sex, ages 6 through 18 years (inclusive) who were receiving treatment with one or more psychotropic medications (stimulants, antidepressants, antipsychotics, mood stabilizers, anxiolytics, or adrenergic agents) were recruited from the mental health outpatient clinics of five academic sites (New York State Psychiatric Institute, Johns Hopkins University, University Hospitals of Cleveland, New York University, Duke University, and Yale University). To be included, children had
RESULTS
Fifty-nine subjects, 45 boys and 14 girls, aged 11.9 ± 3.2 years, were interviewed together with their parents. The demographics and clinical characteristics of the sample are summarized in Table 2.
Administration of the entire SMURF (i.e., inclusive of GI, DSI, and BSR) took from 7 to 70 minutes (mean, 24.6 ± 3.9; median, 21). The GI took an average of 4.3 ± 5.4 minutes (range, 1–23; median, 2). The DSI took an average of 4.2 ± 2.9 minutes (range, 1–13; median, 3). The BSR took an average of
DISCUSSION
This study examined the feasibility and utility of different methods for eliciting AEs in child psychopharmacology. Three increasingly detailed assessments were administered sequentially to outpatient children receiving psychotropic medications and their parents in clinical settings. The sample (N = 59), although limited in size, reflected patient and treatment characteristics typically encountered in child and adolescent psychiatry practice. Most of the children were treated with stimulants,
REFERENCES (10)
- et al.
Review of safety assessment methods used in pediatric psychopharmacology
J Am Acad Child Adolesc Psychiatry
(2003) - et al.
Psychoactive medication prescribing practices for US children: gaps between research and clinical practice
J Am Acad Child Adolesc Psychiatry
(1999) - et al.
National trends in the use of psychotropic medications by children
J Am Acad Child Adolesc Psychiatry
(2002) - et al.
How can we improve the assessment of safety in child and adolescent psychopharmacology?
J Am Acad Child Adolesc Psychiatry
(2003) - et al.
Interrater agreement and reliability measures of SAFTEE: general inquiry vs. systematic inquiry
Psychopharmacol Bull
(1987)
Cited by (78)
A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression
2022, Journal of the American Academy of Child and Adolescent PsychiatryCitation Excerpt :These assessments were overseen by a separate board-certified child psychiatrist (PEC). Assessments included the following: K-SADS-PL; CDRS-R; Quick Inventory of Depressive Symptomatology−Clinician Rated, Adolescent Self Report, and Parent Report [QIDS-A17-CR, QIDS-A17-SR, QIDS-A17-SR(P), respectively]29; Children's Global Assessment Scale (CGAS)30; YMRS; Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER) and Safety Monitoring Uniform Research Form−Modified for this study (SMURF-M)31 to track number of adverse events/side effects (AEs/SE); Satisfaction Survey Baseline−Patient and Parent; and Satisfaction Survey 8 Week−Patient and Parent. The satisfaction survey asked patients and parents their “overall satisfaction with the clinical visit.”
Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study
2019, Journal of the American Academy of Child and Adolescent PsychiatryCitation Excerpt :Interrater reliability was established and maintained with quarterly assessments across investigative sites for the YMRS and CDRS-R. Side effects were assessed at every study visit by direct, open-ended query of the participants and guardians with ascertainment facilitated using the Side Effects Form for Children and Adolescents (SEFCA),37 supplemented by specific items from the UKU Side Effect Rating Scale38 and the Safety Monitoring and Uniform Report Form (SMURF).39 Neurological side effects were assessed using the Neurological Examination for Lithium (NELi)30 and the Neurological Rating Scale (NRS).40
A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension
2017, Journal of the American Academy of Child and Adolescent PsychiatryCitation Excerpt :Participants could be rechallenged (using the same 50-mg multiple) once an AE was resolved. Dependent measures included the caregiver-completed Aberrant Behavior Checklist21,22; vital signs, height, weight, physical examination, and abdominal and hip circumferences; the Safety Monitoring Uniform Report Form23; and clinical laboratory tests (fasting glucose, hemoglobin A1c, insulin, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and the homeostasis model of insulin resistance). Urine or blood pregnancy testing was conducted for girls of childbearing potential.
Adverse Effects of Psychotropic Medications: A Call to Action
2016, Psychiatric Clinics of North AmericaChild/adolescent anxiety multimodal study: Evaluating safety
2015, Journal of the American Academy of Child and Adolescent PsychiatryHigh Probability of Gene-Drug Interactions Associated with Medication Side Effects in Adolescent Depression: Results from a Randomized Controlled Trial of Pharmacogenetic Testing
2024, Journal of Child and Adolescent Psychopharmacology
This research was supported by NIMH contracts N01MH60005 (Dr. Greenhill) and N01MH60016 (Dr. Riddle) and was conducted at the Departments of Psychiatry, Divisions of Child and Adolescent Psychiatry, New York State Psychiatric Institute, New York University Child Study Center, Johns Hopkins University, Yale University, University Hospitals of Cleveland, and Duke University. The authors are grateful for the technical support of Donald McMahon (Nathan Kline Institute) in preparing the study interview forms.
Article Plus (online only) materials for this article appear on the Journal's Web site: www.jaacap.com.
The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the National Institute of Mental Health, the National Institutes of Health, or the Department of Health and Human Services.
Disclosure: Dr. Greenhill has received support (honoraria or grants to do research) from Celltech, Shire, Eli Lilly, McNeil, Alza, Janssen-Cilag, and Novartis. Dr. Abikoff has received support from McNeil, Shire, and Eli Lilly and serves as an advisor to Eli Lilly, McNeil, Shire, and Celltech. Dr. March has received research support from Pfizer (consulting fees, speaker fees, Scientific Advisor), Solvay Pharmaceuticals (speaker fee, consulting fee), Wyeth-Ayerst (research support, consulting fees), Shire (Scientific Advisor), and GSK (consulting fee). Dr. Walkup has received support for research from Pfizer (grant support and honoraria), Janssen (honoraria), and Eli Lilly (grant support and honoraria). Dr. Riddle has received support from Forest, Janssen, Eli Lilly, Pfizer, Sanofi, AstraZeneca, Shire, Mallinckrodt, and Bristol-Myers Squibb. Dr. Chrisman has received support for research from SmithKline Beecham, Wyeth-Ayerst, Somerset, Shire, Eli Lilly, Novartis, McNeil, and Noven. Dr. Findling has received support for research from Abbott, AstraZeneca, Best Practices, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Layton Biosciences, Eli Lilly, Nature's Herbs, New River, Novartis, Noven, Organon, Otsuka, Pharmastar, PPD, Pfizer, Shire, Solvay Pharmaceuticals, Somerset, and Wyeth-Ayerst. The other authors have no financial relationships to disclose.